Jacobson J, Cavalli-Björkman K, Lundström V, Nilsson B, Norbeck M
Acta Obstet Gynecol Scand Suppl. 1979;87:73-9. doi: 10.3109/00016347909157795.
A survey of earlier published studies on treatment of dysmenorrhea with prostaglandin synthetase inhibitors is given and personal clinical experiences are presented. The time when treatment should start in relation to the onset of bleeding is also discussed. A survey of studies published in English and Scandinavian literature yielded 532 patients. Pain relief was experienced in 64 to 100 per cent of the patients in these studies. The incidence of side-effects has generally been low but in a few studies a high incidence was reported. In the current study 34 patients with prinary dysmenorrhea completed the douule-blind, placebo controlled study on naproxen. The patients were treated for two cycles, 16 with naproxen and 18 with placebo. The mean relief score indicated a "slight to good" pain relief in the naproxen group and "no alleviation" in the placebo group. The difference is statistically significant (p = 0.003). Supplementary medication was much more used in the placebo group compared to the naproxen group (p = 0.01). In the placebo group no change whatsoever was demonstrated in alleviation of interference with every-day life, whereas there was a statistically significant improvement in the naproxen group. No major side-effect was registered. Thus none of the subjects withdrew from the study.
本文对先前发表的关于用前列腺素合成酶抑制剂治疗痛经的研究进行了综述,并介绍了个人临床经验。还讨论了治疗应在出血开始后何时开始。对英文和斯堪的纳维亚文献中发表的研究进行的综述共纳入了532例患者。在这些研究中,64%至100%的患者疼痛得到缓解。副作用的发生率总体较低,但在一些研究中报告了较高的发生率。在本研究中,34例原发性痛经患者完成了关于萘普生的双盲、安慰剂对照研究。患者接受了两个周期的治疗,16例服用萘普生,18例服用安慰剂。平均缓解评分显示萘普生组疼痛缓解为“轻微至良好”,安慰剂组为“无缓解”。差异具有统计学意义(p = 0.003)。与萘普生组相比,安慰剂组更多地使用了补充药物(p = 0.01)。在安慰剂组中,日常生活干扰的缓解没有任何变化,而萘普生组有统计学意义的改善。未记录到重大副作用。因此,没有受试者退出研究。